Episodebeskrivelse
Everyone in biotech agrees AI needs more data. Almost no one is willing to pay for it.
If you're trying to build or buy a biotech AI model, you've hit the same wall: predictive performance depends on data your budget doesn't cover, and nobody in the field seems willing to close that gap.
John Androsavich runs Ginkgo Datapoints, the bio AI data arm of Ginkgo Bioworks. He trained as an RNA scientist, spent years on the pharma side deciding which technologies were worth buying, and now sells the raw biological data everyone claims to want.
Ross and John get into why biotech spends a fraction…
Website: corrdyn.com

